OTC Regulatory Pathway Needs NDA Flexibility, Monograph Scope – Sharfstein

Former FDA deputy commissioner Joshua Sharfstein, noting public health advocates’ disappointment with results from Sunscreen Innovation Act requirements, proposes an OTC drug review pathway that combines elements of the NDA and monograph systems and would require legislation to create.